NRx Pharma

NRx Pharma The U.S.

We are NRx – a pioneering and focused CNS biopharma company, dedicated to meeting unmet medical needs for those with suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder (PTSD). Food and Drug Administration (“FDA”) has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.

NRx Pharmaceuticals is focused on the high unmet need for lifesaving treatments for people with severe bipolar depressio...
12/29/2025

NRx Pharmaceuticals is focused on the high unmet need for lifesaving treatments for people with severe bipolar depression and PTSD in the presence of suicidality.

Follow our journey.
NRxPharma.com

$NRXP

NRx creates innovative, life-saving treatments to address unmet medical needs and bring hope to those with chronic conditions. Learn More.

From the NRx Pharmaceuticals family to yours, we wish you a Happy Holiday Season.
12/23/2025

From the NRx Pharmaceuticals family to yours, we wish you a Happy Holiday Season.

12/22/2025

NRx Pharmaceuticals (Nasdaq: NRXP) Eliminates All Balance Sheet Debt

announced the elimination of all balance sheet debt following a strategic equity conversion, strengthening the company’s financial position and flexibility for future growth.

This milestone highlights NRx’s commitment to capital efficiency, strategic restructuring, and shareholder value creation.

READ HERE⬇️⬇️⬇️
https://bit.ly/NRXpressrelease

Watch the newest New to The Street interview here⬇️⬇️⬇️
https://bit.ly/NTTS-RxPharmaAdvancesPTSDandDepressionTreatment

👉🏻Learn more at https://bit.ly/NRXPharmaceuticals

12/15/2025

NRX Pharmaceuticals’ Phase 2 STABIL-B Data Sets the Stage for Breakthrough Progress

presented key findings from its Phase 2 STABIL-B trial at ACNP in 2018, results that played a pivotal role in the FDA granting Breakthrough Therapy Designation for its investigational therapy, NRX-101.

Watch the latest New to The Street interview here⬇️⬇️⬇️
https://bit.ly/NTTS-NRXinterview

👉🏻Learn more at https://bit.ly/NRXPharmaceuticals

Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals presents at NobleCon21 – Nob...
12/11/2025

Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals presents at NobleCon21 – Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

Watch Presentation - https://www.nrxpharma.com/dr-jonathan-javitt-ceo-of-nrx-pharmaceuticals-presents-at-noblecon21-noble-capital-markets-twenty-first-annual-emerging-growth-equity-conference/

$NRXP

Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals presents at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

New analyst report from BTIG - NRXP from the Road. HOPE Roll-Out Suggests Strong Appetite for Shorter Treatments That Ad...
12/10/2025

New analyst report from BTIG - NRXP from the Road. HOPE Roll-Out Suggests Strong Appetite for Shorter Treatments That Address Serious ASIB, PTSD & TRD

Read Report - https://ir.nrxpharma.com/analyst-coverage

$NRXP

Address

1201 N Market Street, Suite 111
Wilmington, DE
19801

Website

Alerts

Be the first to know and let us send you an email when NRx Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to NRx Pharma:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category